Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

NCT04499573 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

B-ALL

Interventions

DRUG: CD19/CD22 CAR-T

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology